Indolent Lymphoma

An investigational chimeric antigen receptor T-cell therapy induced responses among patients with indolent lymphomas, according to topline data released by the agent’s manufacturer.

Targeted therapies have rapidly changed the treatment landscape of indolent non-Hodgkin lymphoma, a heterogenous group of diseases for which individualized care is crucial, according to a speaker at Chemotherapy Foundation Symposium.

The addition of copanlisib to rituximab extended PFS among patients with relapsed indolent non-Hodgkin lymphoma who received prior rituximab-containing therapy, according to topline data released by the agent’s manufacturer.

Kite Pharma has submitted a supplemental biologics license application to the FDA for axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma, according to the agent’s manufacturer.

The development of chimeric antigen receptor T-cell therapy has revolutionized treatment for patients with advanced blood cancers.

Autologous stem cell transplant at first remission for untreated transformed indolent B-cell lymphoma improved duration of disease control but showed trends toward worse overall survival, according to a presenter at ASCO2020 Virtual Scientific Program.

ORLANDO — Combining lenalidomide with obinutuzumab in relapsed indolent lymphoma produced high overall response even in refractory patients and those who failed multiple lines of treatment, according to a presenter at the ASH Annual Meeting and Exposition.

Healio spoke with Shazia K. Nakhoda, MD, about the improvements in screening and diagnosis for CLL.

In this video, Brian Hill, MD, PhD, Director of the Lymphoid Malignancies Program and Staff Physician at the Cleveland Clinic Taussig Cancer Institute, discussed how to address quality of life in a patient with mantle cell lymphoma, a notoriously aggressive and persistent cancer.